Target Engagement of EXL01 in the Prevention of Post-operative Recurrence of Crohn's Disease

Exclusion Criteria

• •Has a not recovered adequately from any toxicity and/or complications from the surgery before the first dose of study intervention
• •Has a current stoma. Inclusion will be possible after continuity restoration (during the 5 weeks following continuity restoration)
• •Has active anal fistula
• •Is scheduled, according to SoC, to receive a biotherapy at the exception of anti-TNF agent in the 6 months after surgery
• •Has had more than 2 past small bowel resections or cumulated intestinal resection superior to 50 cm
• •Has a contraindication to endoscopy or anaesthesia.
• •Is receiving antibiotics at time of randomization or is likely to require antibiotic treatment within 6 weeks of the first dose of EXL01 or placebo.
• •Has a history of hypersensitivity to EXL01 and/or any excipients, which are listed in the Investigator Brochure (IB), and/or to soybean or soy-containing products.
• •Has a not recovered adequately from any toxicity and/or complications from the surgery before the first dose of study intervention
• •Has a current stoma. Inclusion will be possible after continuity restoration (during the 5 weeks following continuity restoration)
• •Has active anal fistula
• •Is scheduled, according to SoC, to receive a biotherapy at the exception of anti-TNF agent in the 6 months after surgery
• •Has had more than 2 past small bowel resections or cumulated intestinal resection superior to 50 cm
• •Has a contraindication to endoscopy or anaesthesia.
• •Is receiving antibiotics at time of randomization or is likely to require antibiotic treatment within 6 weeks of the first dose of EXL01 or placebo.
• •Has a history of hypersensitivity to EXL01 and/or any excipients, which are listed in the Investigator Brochure (IB), and/or to soybean or soy-containing products.